老年冠心病患者血脂现状调查以及二级预防用药对其水平的影响

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (1841 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the status of blood lipids and secondary prophylactic medication in elderly patients with coronary heart disease, and analyze the influence of secondary prophylactic medication on blood lipid control. Methods An epidemiological cross-sectional study from January 2020 to March 2023 was conducted. The general information, blood lipids and secondary prophylactic medication of elderly patients with coronary heart disease admitted to the hospital were investigated to identify the factors affecting blood lipid control of elderly patients with coronary heart disease. Results A total of 536 elderly patients with coronary heart disease were enrolled, including 265(49.44%) patients with hypercholesterolemia, 207(38.62%) patients with hypertriglyceridemia, 274(51.12%) patients with mixed hyperlipidemia, 198(36.94%) patients with low HDL-C, 354(66.04%) patients with inadequately controlled blood lipids, and 182(33.96%) patients with standard blood lipid control. The proportions of patients treated with antiplatelet drugs, β-blockers, lipid-lowering drugs, and ACEI/ARB drugs were 58.40%, 51.49%, 29.29%, and 49.63%. There were significant differences between the inadequately controlled blood lipids group and the standard blood lipid control group in terms of the course of coronary heart disease, diabetes history, the usage rate of lipid-lowering statins, compliance with secondary prophylactic medication, and duration of secondary prophylactic medication. The course of coronary heart disease ≥5 years, diabetes history, no use of lipid-lowering drugs and poor compliance with secondary prophylactic medication were independent risk factors for blood lipid control failure in elderly patients with coronary heart disease. The variance inflation factor (VIF) was under 3. Conclusion Blood lipid abnormalities are common in elderly patients with coronary heart disease, and the status of blood lipid control is not optimistic. Reasonable secondary prophylactic medication, especially standard use of lipid-lowering statins, can lower blood lipid levels in elderly patients with coronary heart disease, which is conducive to obtaining standard blood lipids.

Key words： coronary heart disease blood lipid status survey secondary prophylactic medication

Received: 30 March 2023

PACS:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xiaobo
	RONG Guoling

Cite this article:

ZHANG Xiaobo,RONG Guoling. Status of blood lipids in elderly patients with coronary heart disease and the influence of secondary prophylactic medication on blood lipid levels[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 92-95.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2023/V20/I3/92

[1] Wu Y, Zhu B, Chen Z, et al.New Insights Into the Comorbidity of Coronary Heart Disease and Depression[J]. Curr Probl Cardiol, 2021, 46(3) : 100413.
[2] Shaya GE, Leucker TM, Jones SR, et al.Coronary heart disease risk: Low-density lipoprotein and beyond[J]. Trends Cardiovasc Med, 2022, 32(4) : 181-194.
[3] 朱志鸿, 杨阳, 王云锋, 等. 中国华中地区冠心病和缺血性脑卒中二级预防抗血小板与他汀治疗现况调查[J]. 临床心血管病杂志, 2022, 38(2) : 101-106.
[4] 周艺, 贾立敏, 霍奇文, 等. 冠心病病人二级预防服药依从性预测模型的构建[J]. 护理研究, 2022, 36(11) : 1925-1930.
[5] 郑荣, 南京柱, 高艳红. UA、TG、LDL-C、Plip对冠心病二级预防降脂治疗患者的危险因素研究[J]. 标记免疫分析与临床, 2021, 28(10) : 1770-1775.
[6] 段振娅, 许海燕, 杨跃进, 等. 中国老年急性心肌梗死患者调脂药物应用现状[J]. 中华老年心脑血管病杂志, 2020, 22(7) : 675-679.
[7] 中华医学会心血管病学分会介入心脏病学组, 中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志, 2018, 46(9) : 680-694.
[8] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南 (2016年修订版)[J]. 中华全科医师杂志, 2017, 16(1) : 15-35.
[9] Agrawal H, Choy HK, Liu J, et al.Coronary Artery Disease[J]. Arterioscler Thromb Vasc Biol, 2020, 40(7) : 185-192.
[10] Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al.Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV) : a randomised controlled trial[J]. Lancet, 2022, 399(10338) : 1876-1885.
[11] Shen Q, He P, Wen M, et al.Secondary prevention of coronary heart disease: The effect of a nursing intervention using Cox's interaction model of client health behaviour[J]. J Adv Nurs, 2021, 77(10) : 4104-4119.
[12] Sigamani A, Gupta R.Revisiting secondary prevention in coronary heart disease[J]. Indian Heart J, 2022, 74(6) : 431-440.
[13] 王旭, 李毅, 李晶, 等. 比较不同地域ACS患者PCI术后的二级预防依从性和长期预后[J]. 中华心血管病杂志, 2021, 49(2) : 143-149.
[14] 沈珈谊, 王苏英, 李珊, 等. 浙江省社区中老年人群冠心病患病率调查及危险因素分析[J]. 临床心血管病杂志, 2020, 36(9) : 805-809.
[15] 周迎生, 苏申慧, 汤雅迪, 等. 经皮冠状动脉介入治疗术后发生支架内再狭窄的冠心病患者心血管危险因素分析[J]. 中华老年医学杂志, 2020, 39(4) : 386-390.
[16] 刘于庭, 马欢, 尹晗, 等. 冠心病介入治疗患者非高密度脂蛋白胆固醇达标情况与预后的关系研究[J]. 中国全科医学, 2020, 23 (19) : 2435-2440+2445.
[17] 段振娅, 许海燕, 杨跃进, 等. 中国老年急性心肌梗死患者调脂药物应用现状[J]. 中华老年心脑血管病杂志, 2020, 22(7) : 675-679.